Related Articles
Correlation between immune‑related adverse events and treatment efficacy of anti‑PD1 immunotherapy in patients with esophageal squamous cell carcinoma
Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR‑TKI treatment in advanced NSCLC
Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report
Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations
The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC